Xencor Appoints New CEO, Dr. John Orwin
Ticker: XNCR · Form: 8-K · Filed: Apr 9, 2024 · CIK: 1326732
| Field | Detail |
|---|---|
| Company | Xencor Inc (XNCR) |
| Form Type | 8-K |
| Filed Date | Apr 9, 2024 |
| Risk Level | medium |
| Pages | 6 |
| Reading Time | 7 min |
| Key Dollar Amounts | $0.01, $43 billion, $465,000.00, $2,250,000, $1,000,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, executive-appointment, board-of-directors
Related Tickers: XNCR
TL;DR
Xencor gets a new CEO, John Orwin, replacing Bassil Dahiyat. Board seats also changed.
AI Summary
On April 9, 2024, Xencor Inc. announced changes to its executive team and board of directors. Dr. John Orwin has been appointed as the new Chief Executive Officer, succeeding Bassil Dahiyat. Additionally, Dr. Orwin and Ms. Karen Smith have been elected to the Board of Directors.
Why It Matters
This leadership transition could signal a new strategic direction for Xencor, potentially impacting its drug development pipeline and future collaborations.
Risk Assessment
Risk Level: medium — Leadership changes can introduce uncertainty regarding strategic direction and operational execution.
Key Players & Entities
- Xencor Inc. (company) — Registrant
- Dr. John Orwin (person) — New Chief Executive Officer and Board Member
- Bassil Dahiyat (person) — Former Chief Executive Officer
- Ms. Karen Smith (person) — New Board Member
- April 9, 2024 (date) — Date of Report
FAQ
Who has been appointed as the new CEO of Xencor Inc.?
Dr. John Orwin has been appointed as the new Chief Executive Officer of Xencor Inc.
Who did Dr. John Orwin replace as CEO?
Dr. John Orwin replaced Bassil Dahiyat as CEO.
When was this leadership change reported?
This leadership change was reported on April 9, 2024.
Besides the CEO, who else was appointed to the Board of Directors?
Ms. Karen Smith was also elected to the Board of Directors.
What is Xencor Inc.'s principal executive office address?
Xencor Inc.'s principal executive offices are located at 465 North Halstead Street, Suite 200, Pasadena, California 91107.
Filing Stats: 1,682 words · 7 min read · ~6 pages · Grade level 13.2 · Accepted 2024-04-09 08:20:44
Key Financial Figures
- $0.01 — ich registered Common Stock, par value $0.01 per share XNCR Nasdaq Global Market I
- $43 billion — icensing transactions and the company's $43 billion acquisition by Pfizer in 2023. Before S
- $465,000.00 — eceive an initial annual base salary of $465,000.00 as well as eligibility for discretionar
- $2,250,000 — ock") with an aggregate option value of $2,250,000 pursuant to the Company's 2023 Equity I
- $1,000,000 — of Common Stock valued at approximately $1,000,000 pursuant to the 2023 Plan. The RSUs wil
Filing Documents
- xncr-20240409.htm (8-K) — 34KB
- xncr-20240409xexx991.htm (EX-99.1) — 11KB
- xencora.jpg (GRAPHIC) — 6KB
- 0001326732-24-000012.txt ( ) — 181KB
- xncr-20240409.xsd (EX-101.SCH) — 2KB
- xncr-20240409_lab.xml (EX-101.LAB) — 21KB
- xncr-20240409_pre.xml (EX-101.PRE) — 12KB
- xncr-20240409_htm.xml (XML) — 3KB
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release issued by Xencor, Inc. on April 9, 2024 . 104 Cover Page Interactive Data File (formatted as inline XBRL). 3
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: April 9, 2024 XENCOR, INC. By: /s/ Celia Eckert Celia Eckert General Counsel & Corporate Secretary 4